Project: Candi-NET: Integrating Candidaemia trial samples, Data and Infrastructure to define Novel clinical trial Endpoints and Treatment strategies
| Acronym | Candi-NET (Reference Number: JPIAMR2024_IMPACT-260) |
| Duration | 21/04/2025 - 20/04/2028 |
| Project Topic | The fungal gut commensal Candida is the most common cause of fungal sepsis worldwide, with persistently high (?50%) mortality, contributed to by emerging resistance to first-line antifungal drugs, echinocandins and azoles. Candidaemia clinical trial design is hampered by reliance on binary clinical and mycological endpoints, in which resistance does not feature. We have assembled a unique consortium of 3 European (UK, France, Netherlands) and 1 South African investigator-led, candidaemia clinical cohorts, with Candida clearance and resistance emergence as a cross-cutting theme. By harmonising trial sampling and integrating clinical metadata with diverse -omics datasets from a combined cohort of 600-700 patients, including proteomics, genomics, metabolomics and mycobiome, our methodology will furnish novel, translational insights that will set the CANDI-NET project apart. Our findings will enable patient stratification in clinical trials in candidaemia, as well as validation of biomarkers of pathogen and host treatment response and pathogen resistance emergence as novel clinical trial endpoints. We will establish a network for phase II/III investigator-led trials in Mycology in low (Europe) and high (Southern Africa) Candida resistance burden settings. Our project will thus deliver the infrastructure and tools required to design an adaptive platform trial to test novel interventions to reduce persistently high Candidaemia mortality and mitigate increasing Candida resistance. |
| Website | visit project website |
| Network | JPIAMR-ACTION |
| Call | 5TH JPIAMR-ACTION Joint Call 2024 |